Adverse Reactions of Ultra-low Dose Decitabine in Elderly Patients with Intermediate- to high- risk Myelodysplastic Syndromes

doi:10.19803/j.1672-8629.2021.08.17

Abstract

Abstract: Objective To investigate the clinical efficacy and adverse reactions of ultra-low dose decitabine in elderly patients with intermediate-to high- risk myelodysplastic syndromes (MDS). Methods The clinical data on nineteen patients with intermediate-to high-risk MDS treated with ultra-low dose decitabine between July 1, 2014 and December 31, 2018 was retrospectively analyzed. The effect of age(aged ≥ 65 / <65) on curative effects and adverse reactions was studied. Results Nineteen patients received a total of eighty-one cycles of ultra-low dose decitabine. Eight (aged≥65) of these patients received a total of 26 cycles of treatment. Alteration of the natural course of disease response, complete remission(CR), and hematology improvement-erythrocyte reaction(HI-E) were much less likely among elderly patients than among those under 65 (P values were 0.024, 0.045, 0.024, respectively). There was no significant difference in other outcomes or in the incidence of post-treatment infection or grade III-IV /IV myelosuppression. With the increase of chemotherapy cycles, the incidence of myelosuppression did not increase significantly. Conclusion For elderly patients with intermediate-to high-risk MDS, the treatment with ultra-low dose decitabine can obtain better clinical efficacy without significant increase in adverse reactions.

Key words: ultra-low dose decitabine, myelodysplastic syndromes, elderly patients, intermdeiate-to high-risk, adverse reactions

CLC Number:

R973 R994.141

CHANG Bingqing, GUO Yixian, ZHAO Hong, LAN Xiaoxi, SU Li, SUN Wanling. Adverse Reactions of Ultra-low Dose Decitabine in Elderly Patients with Intermediate- to high- risk Myelodysplastic Syndromes[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 776-779.

References

[1] Chinese Society of Hematology, Chinese Medical Association.Expert consensus on diagnosis and treatment of myelodysplastic syndrome(2014)[J]. Chinese Journal of Hematology(中华血液学杂志), 2014, 11(35): 1024-1048.
[2] Canaani J, Nagler A.Established and emerging targeted therapies in the myelodysplastic syndromes[J]. Expert Rev Hematol, 2016, 9(10): 997-1005.
[3] Ades L, Itzykson R, Fenaux P.Myelodysplastic syndromes[J]. Lancet, 2014, 383(9936): 2239-2252.
[4] Hu RH, Sun WL, Zhao H, et al.Clinical analysis of low-dose decitabine combined with CAG regimen in treatment of elderly patients with acute myeloid leukemia and myelodysplastic syndromes patients with intermediate- or high-risk[J]. Journal of Leukemia and Lymphoma(白血病·淋巴瘤), 2017, 26(3): 166-169.
[5] Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009, 114(5): 937-951.
[6] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
[7] Greenberg PL, Tuechler H, Schanz J, et al.Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12): 2454-2465.
[8] Cheson BD.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2): 419-425.
[9] Chang BQ,Sun WL.Progress of hypomethylating agents in treatment of myelodysplastic syndromes[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(9): 560-563.
[10] Momparler RL.Pharmacology of 5-Aza-2'-deoxycytidine (decitabine)[J]. Seminars in Hematology, 2005, 42(3 Suppl 2): S9-S16.
[11] Mund C, Hackanson B, Stresemann C, et al.Characterization of DNA demethylation effects induced by 5-aza-2'-deoxycytidine in patients with myelodysplastic syndrome[J]. Cancer Research, 2005, 65(16): 7086-7090.
[12] Kantarjian H, Oki Y, Garcia-Manero G, et al.Results of a rando-mized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1): 52-57.
[13] Wang P.Analysis of ultra low dose decitabine cmbined with CAG regimen in the treatment of high-risk myelodysplastic syndrome and abnormal synthesis of refractory leukemia effect[J]. China Continuing Medical Education(中国继续医学教育), 2016, 8(5): 146-147.
[14] Li J, Yao W, Zhou WW, et al.Clinical significance of low dose demethylation treatment of myelodysplastic syndrome[J]. Journal of Huaihai Medicine(淮海医药), 2014, 32(1): 3-5.
[15] Li H, Wang L, Wu Y, et al.Very-low-dose decitabine is effective in treating intermediate- or high-risk myelodysplastic syndrome[J]. Acta Haematologica, 2017, 138(3): 168-174.
[16] Liang L, Wu GC, Nie LR, et al.Efficacy of low dose decitabine combined with CAG regimen in the treatment of high-risk myelodysplastic syndrome and refractory leukemia[J]. Chinese Journal of Gerontology(中国老年学杂志), 2015, 35(8): 2073-2075.